Wiki · Profile

Cerebrolysin

FPF-1070

Nootropic & CNSApproved

Cerebrolysin is a porcine brain-derived peptide preparation classified as a neuropeptide with neuroprotective and neurotrophic properties. Researchers primarily study it for its potential effects on neurological disorders, including dementia and acute ischemic stroke. Key findings from various studies indicate that Cerebrolysin contains significant amounts of enkephalins and other peptide fragments that may enhance mood stabilization and cognitive function, while also modulating mitochondrial activity and neurotrophic factors like brain-derived neurotrophic factor (BDNF). Current research continues to explore its efficacy and safety in treating a range of neurological conditions, with ongoing investigations into its mechanisms of action and potential benefits in combination therapies.

Chemical Profile

Half-Life

INIntranasal

Not applicable

POOral

Poor bioavailability

Pharmacokinetic data is limited, with rapid distribution and elimination observed.

Mechanism

Mechanism of Action

Cerebrolysin exerts its neuroprotective effects primarily through the modulation of the endorphinergic system, enhancing the release of brain-derived neurotrophic factor (BDNF) and stabilizing dopaminergic neurotransmission via the inhibition of kinases such as ABL1, PINK1, and CDK5. Additionally, it activates the CREB/PGC-1α signaling pathway, which is involved in mitochondrial function and neuroprotection, thereby improving cognitive function and reducing anxiety-like behaviors. The precise mechanisms of action remain incompletely understood, particularly regarding its interactions with other neurotransmitter systems.

Research

88 Research Publications

2,007

Total Citations

Human/RCT

1.7

Avg. Influence

2025

Latest

Sort

Filter

01Top

#01

Sonic hedgehog signaling pathway mediates cerebrolysin-improved neurological function after stroke.

AnimalInfluence2.0

137

Researchers observed that Cerebrolysin enhances neurogenesis and improves neurological function after stroke in rats, mediated by the Sonic hedgehog signaling pathway.

10 and 30 mL(human)2.5 ml/kgintraperitoneal(rat)10 consecutive days2.5 mL/kg per dayi.p.(mouse)

PubMed

02Top

#02

The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders.

ReviewInfluence5.0

124

Researchers observed that cerebrolysin mimics neurotrophic factors, promoting brain protection and repair in various neurological disorders, as evidenced by its effects on neurogenesis and cognitive performance.

30 mL for 10 daysnot mentioned(not mentioned)10 days10 and 30 mLnot mentioned(not mentioned)not mentioned60 mLnot mentioned(not mentioned)not mentioned2.5 mL/kg per dayintraperitoneal(mouse)not mentioned

PubMed

03Top

#03

Cerebrolysin for vascular dementia.

Chen Ning, et al. · The Cochrane database of systematic reviews · 2013

Meta-AnalysisInfluence2.0

101

Researchers studied the effects of Cerebrolysin on cognitive function in elderly patients with vascular dementia. They found that Cerebrolysin may improve general cognitive abilities and overall clinical function, although the evidence is not strong enough to recommend it as a standard treatment.

Key findings

01Cerebrolysin showed a beneficial effect on cognitive function as measured by standard assessments.
02The treatment also improved global clinical function in participants.
03Only non-serious side effects were reported, with no significant difference in side effects between treatment and control groups.

PubMed

#04

Apoptosis modulators in the therapy of neurodegenerative diseases.

ReviewInfluence1.0

The review summarized that cerebrolysin supports neuronal survival and may have therapeutic potential in neurodegenerative diseases by modulating apoptosis.

PubMed

#05

Cerebrolysin: a review of its use in dementia.

HumanInfluence1.0

The study demonstrated that Cerebrolysin significantly improved global outcome measures and cognitive ability in patients with Alzheimer's disease compared to placebo in randomized trials.

PubMed

#06

Cerebrolysin for acute ischaemic stroke.

Ziganshina Liliya Eugenevna, et al. · The Cochrane database of systematic reviews · 2020

Human

The study demonstrated that Cerebrolysin probably has little or no beneficial effect on preventing all-cause death in acute ischaemic stroke, with moderate-quality evidence suggesting an increase in non-fatal serious adverse events.

Key findings

01Cerebrolysin probably results in little to no difference in all-cause death rates among stroke patients.
02There is likely no significant difference in the total number of serious adverse events between those treated with Cerebrolysin and those given a placebo.
03The study suggests a potential increase in non-fatal serious adverse events associated with Cerebrolysin use.

PubMed

#07

Neurotrophic activities and therapeutic experience with a brain derived peptide preparation.

AnimalInfluence1.0

Researchers observed that cerebrolysin exhibits neurotrophic and neuroprotective properties, improving cognitive performance in Alzheimer's patients and demonstrating long-lasting effects after treatment cessation.

PubMed

#08

Cerebrolysin improves cognitive performance in rats after mild traumatic brain injury.

AnimalInfluence3.0

The study demonstrated that cerebrolysin improved long-term cognitive function in rats after mild traumatic brain injury, associated with increased neurogenesis and reduced amyloid precursor protein levels.

PubMed

#09

Neuroprotective effects of cerebrolysin, a combination of different active fragments of neurotrophic factors and peptides on the whole body hyperthermia-induced neurotoxicity: modulatory roles of co-morbidity factors and nanoparticle intoxication.

AnimalInfluence1.0

The study demonstrated that Cerebrolysin significantly reduced neurotoxicity and blood-brain barrier disruption in a rat model subjected to whole body hyperthermia.

30 mL for 10 days10 days10 and 30 mL60 mL2.5 mL/kg per dayintraperitoneal(mouse)per day

PubMed

#10

Cerebrolysin reduces amyloid-β deposits, apoptosis and autophagy in the thalamus and improves functional recovery after cortical infarction.

AnimalInfluence2.0

The study demonstrated that Cerebrolysin reduces amyloid-β deposits, apoptosis, and autophagy in the ipsilateral thalamus, leading to improved sensory function after cortical infarction in a rat model.

30 mL for 10 days10 days10 and 30 mL60 mL2.5 mL/kg per dayintraperitoneal(mouse)per day

PubMed

Safety

Safety & Handling

Research Gaps

There is a lack of extensive long-term human trials assessing the efficacy and safety of Cerebrolysin, particularly in diverse populations and various neurological conditions. Additionally, the precise molecular mechanisms underlying its neuroprotective effects, especially in relation to mitochondrial function and the CREB/PGC-1α pathway, remain inadequately understood.

Solubility

Cerebrolysin is soluble in water and commonly used solvents such as saline.

Storage & Handling

Lyophilized

Stable for 2+ years at -20°C, 12 months at 4°C

Reconstituted

Use within 14 days when refrigerated at 4°C

Avoid

Avoid repeated freeze-thaw cycles, direct light

Solvent

Bacteriostatic water or sterile saline recommended

Safety information is derived from published research and may not reflect all known risks. This is not medical advice.

Legal Status

🇩🇪DE

Not approved as a medicinal product. Not a controlled substance. Sale as research chemical is a legal grey area.

🇺🇸US

Not approved by the FDA as a medicinal product. Not a controlled substance.

🇦🇺AU

Not approved by the TGA as a medicinal product.

🇬🇧UK

Not approved by the MHRA as a medicinal product.

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

Community Insights

Publications per Year

49 total

Pricing

Price Comparison

BESTReceptor ChemUK
60mg
$38.09
Price/mg
$0.63/mg
View
RCpeptidesEU
60mg
$81.00
Price/mg
$1.35/mg
View
Oasis LabsUS
60mg
$106.00
Price/mg
$1.77/mg
View
Iron PeptidesUS
60mg
$109.99
Price/mg
$1.83/mg
View
Bulk Peptide WholesaleUS
60mg
$125.00
Price/mg
$2.08/mg
View

Vendor	Amount	Price	Price/mg	Link
BESTReceptor ChemUK	60mg	$38.09	$0.63/mg	View
RCpeptidesEU	60mg	$81.00	$1.35/mg	View
Oasis LabsUS	60mg	$106.00	$1.77/mg	View
Iron PeptidesUS	60mg	$109.99	$1.83/mg	View
Bulk Peptide WholesaleUS	60mg	$125.00	$2.08/mg	View

Top 5 of 6 offers from 6 vendors. Prices updated daily.

See all Cerebrolysin prices

Mechanism

Tools

Reconstitution Calculator

Calculate reconstitution volumes for Cerebrolysin

Serum Level Visualizer

Visualize Cerebrolysin serum levels over time

Mechanism

Related Peptides

Dihexa Pinealon Selank N-Acetyl Semax Amidate Cortagen Semax

Track Cerebrolysin in PepStack

Log your research cycles, set reminders and visualize serum levels.

Download on theApp Store Get it onGoogle Play

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer